Back to Search Results

Effectiveness of liraglutide 3 mg for the treatment of obesity in a real-world setting without intensive lifestyle intervention.

Department of Family Medicine, Seoul National University Bundang Hospital, Seongnam, South Korea. Department of Family Medicine, Jeju National University Hospital, Jeju, South Korea. Department of Internal Medicine, University of Ulsan College of Medicine, Asan Medical Center, Seoul, South Korea. Department of Internal Medicine, Konkuk University School of Medicine, Konkuk University Medical Center, Seoul, South Korea. Department of Family Medicine, University of Ulsan College of Medicine, Asan Medical Center, Seoul, South Korea. Department of Family Medicine, College of Medicine, Hanyang University, Myongji Hospital, Goyang, South Korea. Daejeon Endo Internal Medicine Clinic, Daejeon, South Korea. Department of Family Medicine, Obesity and Metabolic Disease Center, Seongnam Central Hospital, Seongnam, South Korea. Department of Family Medicine, CHAUM Medical Check-Up Center, CHA Bundang Medical Center, CHA University, Seongnam, South Korea. Department of Family Medicine, School of Medicine, Kyungpook National University, Kyungpook National University Hospital, Daegu, South Korea. Department of Endocrinology and Metabolism, Kyung Hee University College of Medicine, Kyung Hee University Hospital, Seoul, South Korea. Department of Internal Medicine, Kosin University College of Medicine, Busan, South Korea. Department of Internal Medicine, Yongin Severance Hospital, Yonsei University College of Medicine, Yongin, South Korea. Department of Internal Medicine, Seoul National University College of Medicine, Seoul National University Bundang Hospital, Seongnam, South Korea. limsoo@snu.ac.kr.

International journal of obesity (2005). 2021;(4):776-786
Full text from:

Other resources

Abstract

OBJECTIVE We investigated the efficacy and safety of liraglutide 3 mg daily in combination with diet and exercise 2, 4, and 6 months after initiation in real-world settings in Korea. METHODS People first using liraglutide starting in 2018 were recruited from ten sites in Korea. Body weight and body mass index (BMI) were measured after 2, 4, and 6 months and compared with baseline values. RESULTS The full cohort comprised 769 participants: 672 in the 2-month group, 427 in the 4-month group, and 219 in the 6-month group. The baseline mean ± standard deviation of BMI and body weight were 32.2 ± 5.1 kg/m2, and 87.5 ± 18.8 kg, respectively. Body weight and BMI decreased after initiation of liraglutide treatment: -2.94 kg and -1.08 kg/m2 at 2 months; -4.23 kg and -1.55 kg/m2 at 4 months, and -5.14 kg and -1.89 kg/m2 at 6 months (all P < 0.001). In the 6-month cohort, 52.5% and 18.3% of subjects lost ≥5% and ≥10% of body weight, respectively. After 6 months, systolic and diastolic blood pressure decreased significantly by 3.90 and 1.93 mmHg, respectively. In those with diabetes mellitus, HbA1c and fasting glucose levels decreased significantly by 1.14% and 27.8 mg/dl, respectively. Among all participants, 27.6% experienced adverse effects, including nausea (20.8%), vomiting (5.2%), diarrhoea (2.5%), and skin rash (3.6%). Documented reasons for discontinuation of treatment were lack of effect (4.4%), adverse events (4.3%), and high cost (3.1%). CONCLUSIONS In real-world settings in Korea, daily treatment with liraglutide 3 mg was associated with clinically meaningful weight loss without serious adverse events.

Methodological quality

Publication Type : Multicenter Study ; Observational Study

Metadata

MeSH terms : Liraglutide ; Obesity